According to a recent report by Reuters, several American companies developing devices similar to e-cigarettes to alleviate medical conditions such as migraines and respiratory diseases continue to face skepticism from health authorities and the public. These companies believe that there is still a long way to go before obtaining approval from health departments, and during this period, they will need to demonstrate the effectiveness of their devices.
It has been reported that Qnovia and MIIST Therapeutics have developed nebulizer devices similar to existing medical nebulizers. These devices convert e-liquid medication into aerosol form for inhalation. Additionally, Greentank has claimed to have developed a new device aimed at addressing safety issues with existing nebulizer devices, which can more effectively treat conditions such as migraines. Experts, including Professor Federico Buonocore, a specialist in pulmonary drug delivery at Kingston University in the UK, believe that these advancements in nebulizer technology will greatly benefit patients.
The existing inhalation drug delivery devices are bulky and difficult to operate, often leading to improper use. Designs similar to e-cigarettes can address these challenges.
These companies claim that inhalation can provide faster pain relief with fewer side effects compared to pills. Inhalation therapy can relieve pain within seconds and has fewer side effects than traditional medications. However, the potential harmful effects of inhalation devices are currently hindering the progress of these projects.
According to data from the World Health Organization, approximately three billion people worldwide suffer from migraines. In addition, there are millions of people suffering from asthma or lung diseases that require inhalation medication. The World Health Organization has stated that e-cigarettes may produce harmful chemicals such as formaldehyde and heavy metals, and the long-term effects are still unclear.
Qnovia and MIIST plan to market their products as smoking cessation aids, available through prescription sales. Greentank, on the other hand, will be using their heating element chips for recreational cannabis and nicotine-containing vapor devices. Currently, Greentank is seeking pharmaceutical partners to support the development of their medication management heating element chips.
Qnovia company plans to submit a drug application in the United States soon and is planning to submit an application to the United Kingdom in 2026, with clinical trials expected to begin in September.
According to reports, tobacco companies such as Philip Morris International (PMI) had previously attempted to enter this market but were unsuccessful. Health officials pointed out numerous cases of failed inhalation devices and health issues.
The CEO of Philip Morris International (PMI) stated that the company did not meet its goals last year because it had been overly optimistic about the market acceptance of non-nicotine industries. A inhalable aspirin product developed by the company was also deemed ineffective after clinical trials last year.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
